## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 35.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. SueWallSt Podcast Explains Class Action Against Baxter International, Inc. (BAX)**
- Source: ABC4 Utah | 20251205T131020 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP has released a podcast detailing a class action securities lawsuit against Baxter International, Inc. (NYSE: BAX). The lawsuit alleges that Baxter made false and misleading statements regarding its Novum LVP product, which suffered from systemic defects causing malfunctions and patient harm. Investors who lost money due to alleged securities fraud between February 23, 2022, and July 30, 2025, are affected by this action.

**2. BAX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!**
- Source: MyHighPlains.com | 20251205T120754 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has announced that a class action lawsuit has been filed against Baxter International, Inc. (NYSE:BAX) and some of its officers. The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects and widespread malfunctions in its Novum LVP products, which exposed patients to serious risks. Investors who purchased Baxter securities between February 23, 2022, and October 29, 2025, are encouraged to join the class action and have until December 15, 2025, to request to be appointed as lead plaintiff.

**3. Levi & Korsinsky Helps Shareholders SueWallSt After Baxter International, Inc. Stock Drops**
- Source: WRIC ABC 8News | 20251204T171500 | Neutral | Relevance: 99%
-  Levi & Korsinsky is helping shareholders file a class action lawsuit against Baxter International, Inc. following alleged securities fraud between February 23, 2022, and July 30, 2025. The firm encourages investors who lost money to take action and offers resources like the SueWallSt podcast and WhatsApp channel for updates on class action news.

**4. Baxter International, Inc. (BAX) Investors: December 15, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: WGN Radio 720 | 20251204T130840 | Neutral | Relevance: 99%
-  Lieff Cabraser Heimann & Bernstein, LLP reminds investors of Baxter International, Inc. (NYSE:BAX) who purchased stock between February 23, 2022, and July 30, 2025, about a securities class action lawsuit with a lead plaintiff deadline of December 15, 2025. The lawsuit alleges that Baxter made misleading statements and failed to disclose critical defects with its Novum LVP medical device, which led to malfunctions, serious injuries, and patient deaths. Following the disclosure of these issues and a temporary pause in shipments of the device, Baxter's stock price fell significantly.

**5. BAXTER INTERNATIONAL INC. (NYSE: BAX) SHAREHOLDER ALERT**
- Source: GlobeNewswire | 20251203T171500 | Neutral | Relevance: 99%
- Bernstein Liebhard LLP reminds investors of an upcoming deadline for a class action lawsuit against Baxter International Inc. The lawsuit alleges securities fraud, claiming Baxter misrepresented the safety of its Novum IQ Large Volume Pump between February 23, 2022, and July 30, 2025. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm by December 15, 2025, to discuss their options or serve as lead plaintiff.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.0x requires aggressive growth execution.
2. Elevated short interest (8.6%): bears positioning against stock.
3. Long-term trend broken: trading 31.3% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.01 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 8.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.01 |
| Forward P/E | 8.0 |
| Current P/E | 7.8 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.1% to -2.3% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Below SMA200 (0.69x), long-term trend not supportive. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.26% (CS: 30) | Weak |
| RSI_14 | 43.2 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 0.904x | Below |
| vs SMA200 | 0.687x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.54
- **Stop Loss:** $17.38 (6.3% risk)
- **Target:** $19.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 431
- **Position Value:** $7,990.74
- **Portfolio %:** 7.99%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*